Cardiac risks of imatinib in chronic myelogenous leukemia (CML) patients who receive allogeneic hematopoietic cell transplantation (Allo-HCT)

被引：0
|
作者：
Burke, M. J. [1 ]
Gursahaney, A. [1 ]
Trotz, B. [1 ]
Luo, X. [1 ]
Baker, K. S. [1 ]
Weisdorf, D. J. [1 ]
Wagner, J. E. [1 ]
Michael, V. R. [1 ]
机构：
[1] Univ Minnesota, Minneapolis, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.7039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7039
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
    Burke, M. J.
    Trotz, B.
    Luo, X.
    Weisdorf, D. J.
    Baker, K. S.
    Wagner, J. E.
    Verneris, M. R.
    BONE MARROW TRANSPLANTATION, 2009, 44 (03) : 169 - 174
  • [2] Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
    M J Burke
    B Trotz
    X Luo
    D J Weisdorf
    K S Baker
    J E Wagner
    M R Verneris
    Bone Marrow Transplantation, 2009, 44 : 169 - 174
  • [3] Allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia - prognostic factors and outcome
    Sakellari, I
    Fassas, A
    Yannaki, E
    Saloum, R
    Lalayanni, C
    Batsis, I
    Stamatopoulos, K
    Eglezou, E
    Kontodimou, A
    Anagnostopoulos, A
    BONE MARROW TRANSPLANTATION, 2003, 31 : S177 - S177
  • [4] Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
    Robin, Marie
    Gras, Luuk
    Gagelmann, Nico
    Koster, Linda
    de Latour, Regis Peffault
    Van Gorkom, Gwendolyn
    Ganser, Arnold
    Itala-Remes, Maija
    Zuckerman, Tsila
    Beguin, Yves
    Schaap, Nicolaas
    Drozd-Sokolowska, Joanna
    Raj, Kavita
    Hayden, Patrick J.
    de Wreede, Liesbeth C.
    Czerw, Tomasz
    Hernandez Boluda, Juan Carlos
    Kroeger, Nicolaus
    Yakoub-agha, Ibrahim
    McLornan, Donal P.
    BLOOD, 2022, 140 : 7585 - 7586
  • [5] Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis
    Boluda, Juan Carlos Hernandez
    Eikema, Dirk-Jan
    Erazo, Nadia
    Kroeger, Nicolaus
    Robin, Marie
    de Witte, Moniek
    Finke, Juergen
    Rambaldi, Alessandro
    Broers, Annoek E. C.
    Raida, Ludek
    Schaap, Nicolaas
    Chiusolo, Patrizia
    Verbeek, Mareike
    Choi, Goda
    Halaburda, Kazimierz
    Kulagin, Alexander D.
    Labussiere-Wallet, Helene
    Gedde-Dahl, Tobias
    Rabitsch, Werner
    Raj, Kavita
    Drozd-Sokolowska, Joanna
    Polverelli, Nicola
    Czerw, Tomasz
    Yakoub-Agha, Ibrahim
    McLornan, Donal P.
    BLOOD, 2022, 140 : 10608 - 10610
  • [6] ABO incompatibility has no effect on the outcome of allogeneic hematopoietic cell transplantation (allo-HCT)
    Sakellari, I
    Stavroylanni, N
    Kalogiannidis, P
    Marantidou, M
    Ganidou, M
    Natse, T
    Batsis, I
    Anagnostopoulos, A
    Fassas, A
    BONE MARROW TRANSPLANTATION, 2002, 29 : S115 - S115
  • [7] Impact of imatinib therapy on the use of allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of the chronic myelogenous leukemia (CML).
    Giralt, S
    Sobocinski, K
    Horowitz, MM
    BLOOD, 2003, 102 (11) : 473A - 473A
  • [8] Effectiveness of allogeneic hematopoietic stem cell transplantation (allo-HCT) in patients transplanted with active myeloid disease
    Liga, Maria
    Spyridis, Nikolaos
    Triantafyllou, Evi
    Marangos, Markos
    Spyridonidis, Alexandros
    BONE MARROW TRANSPLANTATION, 2018, 53 : 495 - 496
  • [9] EXTRAMEDULLARY RELAPSE OF ACUTE MYELOGENOUS LEUKEMIA (AML) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HCT): BETTER PROGNOSIS THAN SYSTEMIC RELAPSE
    Solh, M.
    Kaufman, D. S.
    Defor, T.
    Weisdorf, D. J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S156 - S156
  • [10] The conditioning regimen intensity of allogeneic hematopoietic cell transplantation (Allo-HCT) in chronic myeloid leukemia (CML): The historical case matched comparison of ablative versus reduced intensity regimen
    Gurman, G.
    Arat, M.
    Topecuoglu, P.
    Caglayan, E. A.
    Arslan, O.
    Ozcan, M.
    Akan, H.
    Beksac, M.
    Konuk, N.
    Uysal, A.
    Koc, H.
    Ilhan, O.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 81 - 82
12345